OpenEvidence's AI Chatbot Reaches 65% of U.S. Physicians

In a clinic, the time between a patient's question and a doctor's answer is measured in seconds, not minutes. For decades, that gap has been filled by memory, instinct, and the frantic search through a physical textbook or a clunky digital database. OpenEvidence, a Cambridge-based startup founded in 2022, is betting that gap should be filled by an AI chatbot trained on 35 million peer-reviewed papers, answering in real time at the point of care [Fierce Healthcare, Jan 2026] [clinicalaireport.com]. The bet appears to be working, at least by the metric of sheer adoption: the company reports its free tool is now used by nearly two-thirds of U.S. physicians across more than 15,000 care centers [nbcnews.com] [iheart.com, Oct 2026]. For a company less than four years old, that kind of clinical footprint is almost unprecedented outside of electronic health records themselves.

The Wedge: Free for Doctors, Paid by Pharma

OpenEvidence's product strategy is deceptively simple, built on a classic two-sided model. For clinicians, it offers an AI-powered medical search engine and chatbot that synthesizes evidence from licensed full-text journals like those from the JAMA Network and The New England Journal of Medicine [openevidence.com] [clinicalaireport.com]. The core product is free for verified physicians, removing the friction of procurement committees and individual budgets [openevidence.com]. On the other side, the company monetizes through pharmaceutical and medical-device advertising, with enterprise integrations for health systems developing as a secondary revenue stream [openevidence.com]. This approach has driven staggering usage metrics: the platform reportedly processes 17 million monthly clinical queries and supported about 27 million clinical consultations in a single month last year [iheart.com, Oct 2026] [fqhctalent.com].

A Founder Who Builds Billion-Dollar Tools

The company's trajectory is inextricably linked to its co-founder and CEO, Daniel Nadler. A Harvard-trained economist and published poet, Nadler's previous venture was Kensho Technologies, a financial analytics AI firm acquired by S&P Global for $550 million in 2018 [Forbes, Mar 2018] [The New York Times, Aug 2016]. That exit established Nadler's pattern: building complex, data-intensive tools for expert users. His co-founder and CTO, Zachary Ziegler, brought early large-language-model expertise to the partnership [iheart.com, Oct 2026]. The team is rounded out by a chief medical officer, Travis Zack, an oncologist and researcher from Stanford, who provides clinical credibility [medicine.stanford.edu, Jul 2026]. This blend of AI engineering, commercial scale, and medical authority has proven irresistible to investors.

The Funding Frenzy and Soaring Valuation

OpenEvidence's capital raise reads like a timeline of the AI boom in miniature. In a span of 19 months, the company's valuation reportedly rose from $1 billion to $15 billion, fueled by nearly $660 million in funding across five rounds [clinicalaireport.com] [Fierce Healthcare, Oct 2025]. The roster of investors is a who's who of technology and growth capital, including Google Ventures, Kleiner Perkins, Sequoia, Thrive Capital, Coatue, and DST Global [openevidence.com].

July 2025 Series B | 210 | M USD
October 2025 Series C | 200 | M USD
January 2026 Series D | 250 | M USD

This capital has fueled aggressive growth. Monthly active users reportedly grew from 355 in January 2024 to over 700,000 by June 2026, and the platform logged one million clinical consultations in a single day last March [beckershospitalreview.com] [fqhctalent.com]. The company's primary traction signals focus on ubiquity within the physician workforce.

• Physician penetration. Reported user growth jumped from 25% of U.S. physicians at Series A to 40% by mid-2025, and to a reported 65% by April 2026 [fqhctalent.com].
• Enterprise footprint. The tool is in use at more than 15,000 U.S. hospitals and medical centers, creating a massive network for its advertising business [iheart.com, Oct 2026].
• Engagement depth. The company reports 75% of users access the platform during office hours, with multiple daily uses per active clinician, suggesting it is woven into routine workflow [newsletter.lukesophinos.com].

The Risks in the Room

For all its momentum, OpenEvidence operates in a field where stakes are measured in patient outcomes, not click-through rates. Its model presents several inherent tensions. First, the advertising-based revenue model, while lucrative (with CPMs reportedly reaching $1,000+), creates a perennial conflict-of-interest question in a clinical setting [sacra.com]. The company mitigates this by clearly separating sponsored content and employing features like EvidenceGrade, which provides a real-time assessment of the certainty behind each AI-generated answer [openevidence.com]. Second, the platform is not a regulated medical device. Its answers are informational support, not diagnostic commands, a distinction the company emphasizes. However, as clinicians come to rely on it, the line between decision support and diagnosis may blur in practice.

Competitively, the landscape is evolving. The incumbent, UpToDate by Wolters Kluwer, is a subscription-based, manually curated clinical reference that has been the gold standard for decades. OpenEvidence's AI-driven, conversational interface represents a generational shift in form factor, but it must prove its answers are as reliably accurate over the long term. The company has also faced reputational scrutiny, with competitor Doximity previously accusing it of aggressive recruitment tactics, a claim OpenEvidence has not publicly addressed [Business Insider, Sep 2025].

What Standard Care Looks Like Today

For the patient sitting in an exam room, the standard of care today often involves a waiting period. A physician hears a complex symptom, excuses themselves, and consults a digital textbook or calls a specialist. The information retrieval process is slow, often interrupting the clinical flow. OpenEvidence is attempting to collapse that waiting period to seconds, providing synthesized answers during the consultation itself. The target is any patient population where a clinician might need rapid, evidence-based clarification,from a primary care physician managing a chronic condition like diabetes to an oncologist reviewing the latest trial data for a rare cancer.

The Next Twelve Months

The coming year will be less about user growth and more about deepening the platform's utility and monetization. Watch for expansion of its AI Scribe tool, OpenEvidence Visits, which records and generates clinical notes in real time [openevidence.com]. Enterprise deals with large health systems, moving beyond the free individual physician model, will be a key test of its enterprise value. Furthermore, as the platform's dataset grows, its potential to move from retrospective evidence synthesis to prospective clinical insights could redefine its category. For now, OpenEvidence has achieved a rare feat in digital health: putting a sophisticated AI tool directly into the hands of a majority of its target users, without asking them to pay for it. The multi-billion dollar question is whether that tool can become indispensable enough to build a sustainable, trusted business around the most important decisions in medicine.

Sources

1. [Fierce Healthcare, Jan 2026] JPM26: OpenEvidence makes the case for AI-powered 'medical superintelligence' | https://www.fiercehealthcare.com/ai-and-machine-learning/jpm26-openevidence-makes-case-ai-powered-medical-superintelligence
2. [clinicalaireport.com] OpenEvidence coverage | https://clinicalaireport.com
3. [nbcnews.com] OpenEvidence coverage | https://nbcnews.com
4. [iheart.com, Oct 2026] OpenEvidence Co-founder & CTO Zack Ziegler | https://www.iheart.com/podcast/269-the-heart-of-healthcare-a-84491131/episode/how-a-small-team-built-the-307334105/
5. [openevidence.com] About | OpenEvidence | https://www.openevidence.com/about
6. [Forbes, Mar 2018] Kensho Technologies acquisition | https://www.forbes.com
7. [The New York Times, Aug 2016] Why Poets Can Make Better Search Engines | https://www.nytimes.com/2016/08/10/books/why-poets-can-make-better-search-engines.html
8. [medicine.stanford.edu, Jul 2026] Travis Zack on OpenEvidence and the Future of Medical AI | https://medicine.stanford.edu/news/stories/episodes/travis-zack-medical-ai.html
9. [Fierce Healthcare, Oct 2025] OpenEvidence funding report | https://www.fiercehealthcare.com
10. [beckershospitalreview.com] OpenEvidence user growth report | https://beckershospitalreview.com
11. [fqhctalent.com] OpenEvidence traction report | https://fqhctalent.com
12. [newsletter.lukesophinos.com] OpenEvidence engagement report | https://newsletter.lukesophinos.com
13. [sacra.com] OpenEvidence revenue, valuation & funding | Sacra | https://sacra.com/c/openevidence/
14. [Business Insider, Sep 2025] Doximity recruitment allegations | https://www.businessinsider.com